DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo


company name or ticker

Pozen, Inc. Discusses Q4 2013 Results (Webcast)

Sector Update: Healthcare Stocks Higher Pre-Market; Pozen Rises on Q4 Results

Sector Update: Healthcare

Pozen's Wagon is Tied to Horizon and Sanofi

Horizon's (HZNP) purchase of AstraZeneca's (AZN) rights to Pozen's VImovo and Sanofi's bet on Pozen's cardiovascular drug have big implications for Pozen's future.

Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014

A big mid-stage disappointment sent Avanir's (AVNR) shares tumbling, but the future may not be as bad as some fear.

Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst

Pozen Stock Sees Short Interest Expand By 15.4%

Notes From One-On-One Meetings During San Fran Biotech Week - Day 2

Benzinga's Top #PreMarket Losers

Benzinga's Top Downgrades

See More Articles...